Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study

被引:5
|
作者
Outh, Roderau [1 ]
Lemaire, Anne [1 ]
Mania, Alexandre [1 ]
Berland, Pauline [2 ]
Gerbaud, Laurent [2 ]
Aumaitre, Olivier [1 ]
Andre, Marc [1 ]
机构
[1] Ctr Hosp Univ, Serv Med Interne, Hop Gabriel Montpied, 58 Rue Montalembert, Clermont Ferrand 63003, France
[2] Ctr Hosp Univ, Serv Sante Publ, Hop Gabriel Montpied, Clermont Ferrand, France
关键词
Antineutrophil cytoplasmic antibodies; Vasculitis; Relapse; RHEUMATOLOGY; 1990; CRITERIA; WEGENERS-GRANULOMATOSIS; TREATMENT RESISTANCE; PREDICTORS; OUTCOMES; CLASSIFICATION; RITUXIMAB; RATES;
D O I
10.1007/s10067-019-04816-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the activity of relapsing events (RE) and their mode of presentation in patients with anti-neutrophil cytoplasmic (ANCA)-associated vasculitis (AAV). Methods Patients diagnosed with AAV between 1990 and 2015 experiencing at least one RE were investigated. The different organ involvements were registered during each RE. Presentation at initial onset (IO) and RE were compared. The Birmingham Vasculitis Activity Score was used to assess the activity. Results Ninety-nine patients were followed: 54 patients with 96 RE and 45 patients with none. The rate of RE was 53% with a median time of follow-up of 6.8 years. The mean time to first RE was 2.8 years. Thirty patients experienced one single RE, 15 had 2, 5 had 3, 2 had 4, and 2 had, respectively, 7 and 8. Fifty-five percent of RE had the same features as IO. Compared to IO, some clinical manifestations were less present: constitutional symptoms (29% vs 69%), ear-nose-throat (50% vs 76%), lung involvement (59% vs 76%), peripheral neuropathies (14% vs 24%), arthritis (7% vs 27%), kidney (25% vs 41%), and heart (4% vs 20%) (p < 0.001). Skin, eye, and bowel manifestations were not significantly less involved during RE. The mean Birmingham Vasculitis Activity Score at IO was 9.02 and 5.11 at relapse (p < 0.0001). Among the 96 RE, 46% had a new organ involvement compared to IO: none were life-threatening. Conclusion Global activity of RE in AAV patients is lower than that of IO. Fewer organs are involved in relapses. RE turned out to begin with the same manifestations as IO in most cases.center dot First study looking into clinical characteristics of relapses including mostly granulomatosis with polyangiitis.center dot Around half of patients with AAV seemed to relapse in a similar way compared to the initial diagnosis.center dot The activity score during relapsing events is less important.
引用
收藏
页码:1601 / 1608
页数:8
相关论文
共 50 条
  • [1] Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study
    Roderau Outh
    Anne Lemaire
    Alexandre Mania
    Pauline Berland
    Laurent Gerbaud
    Olivier Aumaître
    Marc André
    [J]. Clinical Rheumatology, 2020, 39 : 1601 - 1608
  • [2] Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis
    Sun, Xiao-Jing
    Li, Zhi-Ying
    Chen, Min
    [J]. RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2023, 4 (01): : 11 - 21
  • [3] Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
    Arends, Christopher Maximilian
    Weiss, Marlene
    Christen, Friederike
    Eulenberg-Gustavus, Claudia
    Rousselle, Anthony
    Kettritz, Ralph
    Eckardt, Kai-Uwe
    Chan, Willy
    Hoyer, Kaja
    Frick, Mareike
    Bullinger, Lars
    Bieringer, Markus
    Schreiber, Adrian
    Damm, Frederik
    [J]. HAEMATOLOGICA, 2020, 105 (06) : E264 - E267
  • [4] A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
    Moura, Marta Casal
    Branco, Carolina
    Martins-Martinho, Joana
    Ferraro, Jose Luis
    Berti, Alvise
    Nogueira, Estela
    Ponte, Cristina
    [J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [5] Influenza vaccination and anti-neutrophil cytoplasmic antibody-associated vasculitis
    Wiwanitkit, Viroj
    [J]. NEPHROLOGY, 2015, 20 (07) : 511 - 512
  • [6] Novel Therapies for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
    Richard W. Lee
    David P. D’Cruz
    [J]. Drugs, 2008, 68 : 747 - 770
  • [7] Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis
    Tervaert, JWC
    Stegeman, CA
    Kallenberg, CGM
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (02): : 211 - 217
  • [8] Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis
    Hruskova, Zdenka
    Geetha, Duvuru
    Tesar, Vladimir
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 : i159 - i163
  • [9] AN OVERVIEW OF PHARMACOTHERAPY FOR ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
    Stasi, R.
    [J]. DRUGS OF TODAY, 2010, 46 (12) : 919 - 928
  • [10] Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis
    Alberici, Federico
    Martorana, Davide
    Vaglio, Augusto
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 : i37 - i45